MaxVal Blog

    Filter by Category
    Filter by Category

    Go Back to Homepage

    MaxVal Releases Max-IDS™ 4.0.2

    MaxVal announces the latest upgrade to its information disclosure statement software, Max-IDS, version 4.0.2.

    This new version includes multiple enhancements and new features, including:

    • Enhanced, high-speed import process for citations and non-patent literature, which eliminates manual effort and thereby reduces data entry errors.
    • New reference aging system helps avoid  Patent Term Adjustment (PTA) delays and supplemental IDS fees.
    • Expanded authentication and integration capabilities simplify deployment, eliminate password complexity for users and enhances connectivity with docketing systems.
    • Updated user-friendly dashboards, reports and alerts ensure users have quick, easy access to critical data needed to ensure timely filing of IDSs.

    “As a leader in IDS management, we are focused on delivering innovative solutions for our Max-IDS™ clients,” says Phil Henderson, SVP Commercialization of MaxVal.  “Version 4.0.2 reinforces Max-IDS’s position as the most advanced and most used reference management tool in the market, setting the new standard for efficiency and simplicity.”

    MaxVal-Max-IDS-V4

    Max-IDS™ helps clients better manage their patent/reference library and simplifies the process of comparing and citing references across families and technology categories.  In addition to the enhancements in the new release, existing clients of Max-IDS™ benefit from:

    • Efficient management of cross-citations
    • Reduced risk of uncited references
    • Easy access to citations
    • Reduced supplemental IDS filing and RCE costs
    • Elimination of corrupted files

    For more information on Max-IDS 4.0.2, please visit www.max-ids.com or email caitlyn@maxval.com.

    Go Back to Homepage

    Hot Topics in Tech | September 2018 Newsletter | Maxval
    MaxVal Releases Next Generation Patent Prosecution and Business Decision Tool, symphony® AI

    About Author

    MaxVal
    MaxVal

    Related Posts
    MaxVal Sponsoring and Exhibiting at Upcoming Conferences
    MaxVal Sponsoring and Exhibiting at Upcoming Conferences
    Generic Players to Benefit from Paragraph IV Approvals amidst FDA’s Push for Transparency and Competition
    Generic Players to Benefit from Paragraph IV Approvals amidst FDA’s Push for Transparency and Competition
    MaxVal expands with new Professional Services Organization
    MaxVal expands with new Professional Services Organization

    Comment

    Subscribe To Blog

    Subscribe to Email Updates